Clinical trials
Phase 1 trials in Vietnam
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 3 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Recruiting | 5 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vinmec Research Institute of Stem Cell and Gene Technology | 11 |
| Nanogen Pharmaceutical Biotechnology Joint Stock Company | 4 |
| Centre of Clinical Pharmacology, Hanoi Medical University | 3 |
| Institute of Vaccines and Medical Biologicals, Vietnam | 3 |
| Hai Yen Eye Care | 2 |
| Haiphong University of Medicine and Pharmacy | 2 |
| Cho Ray Hospital | 1 |
| Chulalongkorn University | 1 |
| Hoffmann-La Roche | 1 |
| Holterman, Ai-Xuan, M.D. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 3 |
| Influenza, Human | 3 |
| Biliary Atresia | 2 |
| Breast Neoplasms | 2 |
| Liver Cirrhosis | 2 |
| Myopia | 2 |
| Acne Vulgaris | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Anorexia | 1 |
| Autoimmune Diseases | 1 |
Trials
Showing 26 to 35 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.